retatrutide mechanism gip glp-1 glucagon triple agonist Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Retatrutide Guide 2023: Weight Loss,

Description

Could this drug made for type 2 diabetes be a game changer for heart disease too

The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis

The cardiovascular side effects that sank sibutramine are still being studied

Clinical trials, including phase 2 and 3 studies, have reported significant improvements in liver histology, including MASH resolution and decreased hepatic fat content, with GLP-1RA therapy (6, 7)

Methods In this open-label, single-center, casecontrol pilot study, patients with IIH (pwIIH) and a body mass index (BMI) of 30 kg/m 2 were offered to receive a GLP-1-RA (semaglutide, liraglutide) in addition to the usual care weight management (UCWM)